跳至主要内容
临床试验/ACTRN12609000760279
ACTRN12609000760279招募中未知

Safety and Feasibility of a Transurethral Endoscopic Procedure for the Luminal Restoration of the Prostatic Urethra in males with benign prostatic hyperplasia: A Preliminary Investigation

eoTract, Inc.0 个研究点目标入组 70 人开始时间: 2009年9月2日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
55 Years 至 o limit(—)
性别
Male

入选标准

  • Diagnosis of lateral lobe symptomatic BPH
  • - IPSS Symptom score >13
  • - Peak urine flow rate> than 5ml/sec but
  • <12ml/sec on a voided volume > 125 ml
  • - Prostate volume >20 grams to <100
  • - American Society of Anesthesiologists
  • (ASA) risk group class I-III
  • - Normal microscopic urinalysis
  • - Stable prostate-specific antigen (PSA)
  • over two years, or agrees to undergo a
  • pre-treatment transrectal ultrasound and
  • prostate tissue biopsy, if clinically
  • indicated. Biopsy not required if
  • performed within 6 months of treatment

排除标准

  • - Mental capacity, dementia or inability to
  • give informed consent.
  • - Subject in retention, or with a previous
  • history of urinary retention.
  • - Post void residual volume >250 ml by
  • Ultrasound.
  • - Prostate gland with obstructive median
  • lobe or prominent bladder neck requiring
  • intervention.
  • - History of illness/symptoms or surgery
  • that may confound results of study, or
  • pose additional riskto subject.
  • - Patient with a life expectancy of less than
  • - Previous prostate surgery, dilation, stent,
  • laser, hyperthermia (ie non-
  • pharmaceutical prostate treatment).
  • - PSA > 10 ng/ml.
  • - Known, or suspected urological conditions
  • which may effect voiding function such
  • as confirmed or suspected malignancy
  • of the bladder or prostate, previous
  • pelvic irradiation or radical pelvic
  • surgery, neurogenic bladder and/or
  • sphincter abnormalities, cystolithiasis
  • or haematuria within 3 months,
  • urinarytract infection, urethral
  • strictures, bladder neck contracture,
  • active clinical prostatitis, bladder
  • pathologies or diabetes mellitus
  • affecting bladder function.
  • - Compromised renal function (serum
  • creatinine > 1.58 mg/l or > 0.1 mmol/L)
  • (ref: medcalc version 5.3 palm/os)
  • (medcalc.med-ia.net)
  • - Previous rectal surgery, other than
  • hemorrhoidectomy, that may have
  • distorted the pelvic anatomy, or any
  • implants in the pelvic/femoral
  • - Subject interested in future fertility.
  • - Concomitant medications: beta-blockers,
  • antihistaminics, anticonvulsants, and
  • antispasmodics within 1 week of
  • treatment unless there is documented
  • evidence that the subject has been on
  • the same drug dose for at least 6
  • months with a stable voiding pattern
  • (the drug dose should not be altered or
  • discontinued for entrance into or
  • throughout the study).
  • - Anti-coagulant medication other than
  • 另有 20 项未显示

研究者

发起方
eoTract, Inc.

相似试验